The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics Today, Company discloses first clinical data ...

Company to host conference call on Wednesday, March 17 at 8:30 am EST ·First anti-tumor activity observed in heavily pre-treated solid cancer patients during early phases of dose escalation ·Tumor ...

GSK is doubling down on a retreat from the land of T-cell receptors (TCRs), terminating a partnership with Immatics that held the potential for up to $600 million in biobucks. The pact was penned in ...

Despite the hype around adoptive T-cell therapies, it’s still a challenge to find therapeutic targets that are consistent across tumor types and aren’t expressed in healthy cells. Now, a team of ...

Houston, Texas and Tuebingen, Germany, July 9, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting ...

FILE PHOTO: Syringes with needles are seen in front of a displayed Moderna logo in this illustration taken (Reuters) -Moderna said on Monday it has struck a deal with German drug developer Immatics ...

RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer types Regulatory activities ...

ACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on heavily pre-treated 11 patients in Phase 1b dose expansion Cohort A with median duration of ...

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Immatics (NASDAQ:IMTX) stands against other ...

Moderna Inc. agreed to pay German biotechnology company Immatics NV as much as $1.8 billion in a broad-ranging, multiyear collaboration on developing cancer therapies using messenger RNA and other ...